View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
February 9, 2021updated 18 Feb 2021 10:06am

Ampio open to CRO offers to run Phase I long hauler Covid study scheduled to start 1Q, CEO says

Ampio Pharmaceuticals welcomes CRO pitches for a Phase I trial of nebulised Ampion for "long hauler" Covid patients with a potential 1Q trial start, CEO Mike Macaluso said.

By William Newton

Ampio Pharmaceuticals welcomes CRO pitches for a Phase I trial of nebulised Ampion for “long hauler” Covid patients with a potential 1Q trial start, CEO Mike Macaluso said.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Though Phase I design details have not yet been finalised, the trial will likely initiate by recruiting around 25 patients from one site who have persistent trouble breathing following a confirmed Covid-19 infection, Macaluso added. Ampio is based in Englewood, Colorado.

As Ampio gathers results from the first 25 patients, it would plan to expand the trial to include additional sites and study other long hauler Covid symptoms, such as long-term blood clotting, he noted. The ideal CRO would have strong relationships with potential sites that could facilitate this quick study expansion when needed, he added.

Phase I treatment period will likely last five–seven days, with pulmonologists performing lung x-rays before and after treatment to determine Ampion’s effect, Macaluso said. The trial will have several efficacy endpoints, including oxygen uptake and patient-assessed symptom scales, in an effort to elucidate the best measure for quantifying patient improvement, he added.

In the initial 25 patients, Ampion will be given as a nebulised formulation, Macaluso said. However, the company aims to later refine the Phase I protocol to treat patients with different formulations of the drug depending on their symptoms, he added. Systemic complications may be best treated with intravenous (IV) Ampion while severe lung complications may be best treated with both IV and nebulised formulations, he explained.

By targeting both lung-specific and systemic inflammation, Ampion could prove effective at combatting the persistent, long-term Covid-19 symptoms seen in many patients, Macaluso said. Ampion works by repressing inflammatory cytokines while also activating immunomodulating proteins responsible for resolving inflammation, as per the company website. Long hauler Covid, also known as long Covid or chronic Covid syndrome, covers patients experiencing long-term symptoms in the weeks or months following a Covid-19 infection, including fatigue and respiratory and cognitive complications.

Ampion is also under investigation in other Covid-19 settings. Ampio reported early positive data from a 40-patient Phase I trial in Covid-19 patients with respiratory distress. Ampion led to better all-cause mortality and greater clinical improvement compared to standard of care, with no drug-related serious adverse events, according to a 01 February company press release. In addition, Ampio initiated a study of Ampion IV in the US and Israel for patients with moderate-to-severe Covid-19, as per a 4 January press release.

Ampio has a market cap of $360.9m.

William Newton is a Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology